Sigyn Therapeutics, Inc. financial data

Symbol
SIGY on OTC
Location
Beverly Hills, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.92% % -78%
Quick Ratio 1.2% % -26%
Debt-to-equity -103% % 5.6%
Return On Equity 62% % -42%
Return On Assets -1996% % -74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,605,377 shares
Common Stock, Shares, Outstanding 1,605,377 shares 13%
Entity Public Float $3,605,453 USD 94%
Common Stock, Value, Issued $161 USD 13%
Weighted Average Number of Shares Outstanding, Basic 1,605,377 shares 27%
Weighted Average Number of Shares Outstanding, Diluted 1,605,377 shares 27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $140,101 USD -84%
General and Administrative Expense $1,701,601 USD -8.7%
Operating Income (Loss) $1,880,108 USD 32%
Nonoperating Income (Expense) $1,340,964 USD -8.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $3,221,072 USD 19%
Net Income (Loss) Attributable to Parent $3,221,072 USD 19%
Earnings Per Share, Basic -1 USD/shares 39%
Earnings Per Share, Diluted -1 USD/shares 39%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $85,571 USD -48%
Inventory, Net $50,000 USD 0%
Other Assets, Current $1,300 USD -97%
Assets, Current $85,571 USD -68%
Property, Plant and Equipment, Net $8,322 USD -40%
Operating Lease, Right-of-Use Asset $97,181 USD -37%
Other Assets, Noncurrent $50,000 USD 141%
Assets $135,571 USD -68%
Accounts Payable, Current $773,604 USD 26%
Liabilities, Current $3,989,491 USD -6.7%
Operating Lease, Liability, Noncurrent $37,501 USD -66%
Liabilities $6,052,780 USD 39%
Retained Earnings (Accumulated Deficit) $17,379,978 USD -23%
Stockholders' Equity Attributable to Parent $5,917,209 USD -51%
Liabilities and Equity $135,571 USD -68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $294,446 USD -25%
Net Cash Provided by (Used in) Financing Activities $295,197 USD 15%
Common Stock, Shares Authorized 100,000,000 shares -90%
Common Stock, Shares, Issued 1,605,377 shares 13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $751 USD -96%
Deferred Tax Assets, Valuation Allowance $3,958,470 USD 31%
Operating Lease, Liability $109,800 USD -37%
Depreciation $2,724 USD -54%
Lessee, Operating Lease, Liability, to be Paid $114,159 USD -41%
Operating Lease, Liability, Current $72,300 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $54,225 USD -32%
Lessee, Operating Lease, Liability, to be Paid, Year One $59,934 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $4,358 USD -77%
Lessee, Operating Lease, Liability, to be Paid, Year Three $54,225 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $4,008,548 USD 31%
Preferred Stock, Shares Issued 1 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Operating Lease, Payments $19,522 USD 3%
Additional Paid in Capital $11,462,608 USD 12%
Preferred Stock, Shares Outstanding 1 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%